Spero Therapeutics (SPRO) Non Operating Income (2019 - 2026)

Spero Therapeutics (SPRO) has reported Non Operating Income for 8 consecutive years, with $374000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income fell 49.73% year-over-year to $374000.0; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (down 58.4% YoY), and the FY2025 full-year result was $2.5 million, down 47.47% from the prior year.
• Non Operating Income advanced to $374000.0 in Q2 2026 per SPRO's latest filing, from $335000.0 in the prior quarter.
• Across five years, Non Operating Income topped out at $1.3 million in Q1 2024 and bottomed at -$2.6 million in Q1 2022.
• Historically, Non Operating Income has averaged $429333.3 across 5 years, with a median of $856000.0 in 2022.
• The widest YoY moves for Non Operating Income: up 5200.0% in 2022, down 13010.0% in 2022.
• Over 5 years, Non Operating Income stood at $847000.0 in 2022, then rose by 23.49% to $1.0 million in 2023, then climbed by 7.74% to $1.1 million in 2024, then sank by 66.64% to $376000.0 in 2025, then declined by 0.53% to $374000.0 in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $374000.0, $335000.0, and $376000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.